Cancer Vaccine Equipment
-
Manufactured by Scancellbased in UNITED KINGDOM
ImmunoBody vaccines are designed to generate potent T cell responses capable of a broad anti-tumour effect. They are DNA vaccines that encode a protein in the form of an antibody, but the parts of the antibody that would normally bind to the target protein are replaced with epitopes from a cancer ...
-
Manufactured by Khloris Biosciences, Inc.based in USA
iPSC vaccination presents a differentiated approach to cancer treatment, targeting a panoply of antigens, leveraging the patient's immune system for optimized antigen presentation, and engaging both cellular and humoral ...
-
Manufactured by Virometix AGbased in SWITZERLAND
Effective antigen delivery and a strong and durable response is the basis for successful cancer vaccines. The SVLP approach, with its modular and flexible design, the inherent adjuvant properties and other immune system activators, lends itself to the development of particle-based vaccines against cancer: SVLPs displaying ...
-
Manufactured by Scancellbased in UNITED KINGDOM
Scancell’s lead ImmunoBody cancer vaccine, SCIB1, is being developed for the treatment of patients with metastatic melanoma. SCIB1 incorporates specific epitopes from the proteins gp100 and TRP-2, which were identified from the cloning of T cells from patients who achieved spontaneous recovery from melanoma skin cancers. Both proteins ...
-
Manufactured by Ardigenbased in POLAND
Quick solution for effective immune responses in clinical trials; We have created an Artificial Intelligence platform dedicated to being a part of the therapeutic cancer vaccine development. The ArdImmune Vax platform uses sequencing data to generate and prioritize antigen targets for cancer vaccines and T-cell ...
-
Manufactured by Scancellbased in UNITED KINGDOM
Modi-1 is the first vaccine based on Scancell’s Moditope® platform. The vaccine is composed of a combination of three peptides from two target antigens that are commonly modified in cancer cells. The first is the cytoskeletal protein, vimentin, which is preferentially digested during autophagy. All mesenchymal tumours such as ...
-
Manufactured by Scancellbased in UNITED KINGDOM
SCIB2 is the second cancer vaccine based on the ImmunoBody® technology and encodes a modified antibody engineered to express the cancer antigen NY-ESO-1. This is a well-characterised and validated cancer target, being overexpressed in several tumour types including synovial sarcomas, oesophageal, liver, gastric, prostate and ...
-
Manufactured by Scancellbased in UNITED KINGDOM
The Modi-2 vaccine exploits a second post-translational modification, stimulating the production of CD4 T cells using tumour-associated peptide epitopes in which the lysine residues are converted to homocitrulline. This change occurs via a process known as carbamylation, leading to a change in molecular charge which, in turn, alters ...
-
Manufactured by ViciniVax BVbased in NETHERLANDS
Our first product candidate Vvax001, a therapeutic cancer vaccine against (pre)malignant cervical lesions, is currently in clinical development. We outsource process development and GMP manufacturing to experienced CMO’s, leading to a first clinical trial, which has been started in ...
-
Manufactured by Enteromebased in FRANCE
OncoMimicsTM vaccines are a specific combination of bacterial peptides, derived from bacteria present in the gut microbiome, that closely mimic either overexpressed tumor-associated antigens (TAAs) or lineage-specific markers in solid and liquid tumors, respectively. ...
-
based in USA
Immunotherapeutic cancer vaccines have generated a lot of interest from oncologists since it was discovered that immune activation can lead to a specific antitumor response.1 However, despite initial progress, most cancer vaccines have failed to drive sufficient tumor immunogenicity, leading to poor clinical responses.1 The ...
-
Manufactured by Elicio Therapeuticsbased in USA
Our lymph node-targeted mKRAS cancer vaccine; Our Amphiphile (AMP)-powered lead candidate, ELI-002, generates a robust immune response against mutant Kristen rat sarcoma (mKRAS), with the potential to offer patients a stronger fight against the most aggressive cancers. Preliminary data have shown that ELI-002 produces a potent mKRAS-specific ...
-
Manufactured by Enteromebased in FRANCE
EO4010 is an innovative, off-the-shelf therapeutic cancer vaccine currently in discovery. EO4010 peptides combination will include two OncoMimics (bacterial peptides) already used in EO2401 and one or two additional peptides in an indication with high unmet medical need and market potential. ...
-
Manufactured by Enteromebased in FRANCE
EO2463 is an innovative, off-the-shelf therapeutic cancer vaccine discovered by Enterome. EO2463 combines four OncoMimics peptides (bacterial peptides) of B lymphocyte-specific lineage markers. The clinical rationale behind targeting these specific lineage cell markers is to induce the full depletion of malignant B lymphocytes enriched in ...
-
Manufactured by 2A Pharma ApSbased in DENMARK
2A Pharma’s AAVLP-HER2/Neu peptide vaccine candidate has in laboratory tests been shown to induce antibodies specific to human HER2. In mouse models, regression of breast cancer tumors was observed after vaccination. In a proof-of-principle study carried out at the Medical University of Vienna, Austria, supported by Medigene ...
-
based in USA
Ombipepimut-S Emulsion (DSP-7888) is an investigational immunotherapeutic cancer vaccine containing 2 peptides that induce WT1-specific cytotoxic T lymphocytes (WT1-CTLs) and helper T cells to attack WT1-expressing cancerous cells found in various types of hematologic malignancies and solid tumors.1,2 Researchers have identified that adding ...
-
Manufactured by 2A Pharma ApSbased in DENMARK
Head and neck cancers represent the sixth most common cancer worldwide, resulting in more than 350,000 deaths/year. Our AAVLP-HNC vaccine uses our mimotope selection technology and has the potential to minimize side effects, improve efficacy, and markedly reduce treatment costs. This will address an unmet medical need and benefit ...
-
Manufactured by eTheRNAbased in BELGIUM
Therapeutic area: cancer vaccines; Systemic, intravenous (IV) ...
-
Manufactured by leon-nanodrugs GmbHbased in GERMANY
for rapid production of individual batches without the risk of cross-contamination, and eliminates the need for cleaning and sterilization steps in between batches. NANOme is highly adaptable for clinical use in personalized medicines such as therapeutic cancer vaccines and as an adjunct to platforms for CAR-T. ...
-
Manufactured by Lineage Cell Therapeutics, Inc.based in USA
VAC2 is an allogeneic, or non-patient specific, cancer vaccine candidate designed to stimulate patient immune responses to telomerase which is commonly expressed in cancerous cells but not in normal adult cells. VAC2, which is produced from our pluripotent cell technology using a directed differentiation method, is comprised of a ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you